Baylor researchers develop new drug to overcome cancer treatment resistance

Drug targets tumor survival defenses

The experimental drug named CS18 is designed to disable several biological defenses that tumors use to survive therapy. Researchers found that this approach strengthens existing treatments and restores sensitivity in lung cancer cells that had previously become resistant. The study provides early evidence supporting further investigation of the compound as a potential future cancer treatment.

Study shows slowed tumor growth

Animal models demonstrated that CS18 successfully slowed tumor growth while interfering with a broader control center involved in multiple cancer-promoting processes. Dr Weei-Chin Lin noted that therapeutic resistance remains a main obstacle to achieving effective and durable cancer treatments for patients. The new drug addresses the issue where cancer cells activate compensatory pathways to overcome the toxic effects of standard therapy.